PubMed · 3561567
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
L H Booij. 1987-02-14. [Halothane and hepatitis].. https://pubmed.ncbi.nlm.nih.gov/3561567/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
Cholestasis is one kind of reaction of the liver to intolerable drugs. It is estimated that 2% of the patients who are treated for icterus in hospital suffer from drug intolerance. A differentiation is made between obligtory and optional liver-damaging substances. The latter are clinically important because they occur far more frequently. In principle nearly every drug may cause cholestasis, which must be taken into consideration especially with newly introduced drugs, e.g. in cholestasis caused by co-enzyme-A-reductase inhibitors in the treatment of hypercholesterinaemia. Cholestasis is most likely to occur after administration of the following group of substances: antiarrhythmics, antibiotics, tuberculostatics, salicylates, immunosuppressives, narcotics, tranquilizers, some antirheumatics, antidepressants, anticonvulsives, and sex hormones. This list does not claim to be complete or to be in any order of frequency.
The appearance of toxic effects upon consumption of delayed release verapamil at therapeutic doses (120 mg/12 h) in a 64 year old patient with renal failure is described. The patient presented hypotension, bradycardia due to auriculoventricular block, hepatotoxicity, slight hyperglycemia, hyperpotassemia and metabolic acidosis with increased anionic gap. The picture remitted spontaneously with support treatment following discontinuation of the medication. The pathogenesis of the syndrome and the possibility that the hepatotoxicity was the triggering factor are discussed. Extreme precaution is recommended when this type of drugs is used in severe uremic or diabetic patients.